Dossier assessment
Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Report documents
-
Dossier assessment
Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Project details
- Project no.
- G23-27
- Commission
- Commission awarded on 16.10.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG, the GBA conducts a commenting procedure. Following the hearing, the GBA decides on the extent of the added benefit. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA Website.
- DOI
- https://doi.org/10.60584/G23-27
Connected Projects
-
Dossier assessment
Epcoritamab (DLBCL, third line) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Epcoritamab (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed